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Background: Dexmedetomidine (Dex) provides sedation and analgesia by acting on central alpha-2 receptors and
is suitable for use after extubation because it has little respiratory depression. Considering the sympathoinhibitory
and anxiolytic action of Dex, there is the possibility that Dex might reduce the incidence of atrial fibrillation (AF),
which is recognized as a common complication after cardiovascular surgery. We investigated whether the
postoperative incidence of AF decreased in patients who received Dex only during the nighttime in the
intensive care unit (ICU).
Methods: We retrospectively reviewed ICU charts to determine the incidence of AF and associated factors during
the 2-day period after tracheal extubation in patients who underwent cardiovascular surgery from November 2009
to November 2010. The patients were divided into a Dex group (n = 16) and a non-Dex group (n = 29).
Results: There were no differences in AF risk factors except for diabetes between the two groups. The average rate
of Dex administration was 0.3 ± 0.2 μg/kg/h. There were also no differences between the groups in heart rate
during the daytime, central venous pressure, body temperature, white blood cell count, serum level of C-reactive
protein, catecholamine use, beta-blocker use, and amount of fentanyl. AF developed in one patient in the Dex
group (6.3 %) and ten patients in the non-Dex group (34.5 %) during the observation period, and the difference
was significant (p = 0.035). None of the risk factors for AF was significantly associated with AF in univariate analysis;
however, multivariate logistic regression analysis using age, Dex use, and beta-blocker use, extracted because their
p values in univariate analysis were not exceeding 0.15, showed that Dex use was the only factor associated with
the development of AF (p = 0.045, odds ratio 9.75 [1.05–90.8]).
Conclusions: The results suggest that adequate sedation with Dex during the nighttime can reduce the incidence
of AF in cardiovascular surgery patients after extubation.
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Atrial fibrillation (AF) is reported to occur in up to 40 %
of patients in the immediate postoperative period after
cardiovascular surgery despite improvements in anesthesia,
surgical technique, and other medical therapies [1–4].
Patients who develop AF after cardiovascular surgery
have increased mortality, morbidity, and length of hos-
pital stay with increased health care costs [5–8].
The pathogenesis of postoperative AF is thought to be
multifactorial. Preoperative factors such as increased
age, reduced left ventricular function, atrial fibrosis and
enlargement, and preexisting electrocardiographic ab-
normalities are thought to contribute to the develop-
ment of AF. In addition, intraoperative factors such as
reperfusion injury, systemic inflammation, hemorrhage,
and hemostasis may also play a role in postoperative AF
[1, 9]. The precise contribution of each of these risk fac-
tors and the role of postoperative cardiac autonomic
tone in the development of AF have not been clearly
defined [5, 10–13].
Dexmedetomidine (Dex), an alpha-2 agonist, has
unique effects providing both sedation and analgesia
by acting on central alpha-2 receptors in the locus cer-
uleus. These properties are useful in the intensive care
unit (ICU) for relieving anxiety and pain and syn-
chronizing mechanical ventilation with spontaneous
respiratory effort [14–17]. Dex can also be used for
sedation after tracheal extubation because it has little re-
spiratory depression compared with gamma-aminobutyric
acid receptor agonists, which are generally used in the
ICU [14, 16, 17].
In our ICU, we previously did not administer seda-
tive drugs to patients after tracheal extubation. How-
ever, as the use of Dex became widespread, we started
to administer this agent to more patients after extuba-
tion. In our current clinical practice, we infuse Dex
only during the nighttime to facilitate a natural sleep
cycle. This practice helps maintain a circadian rhythm
and promotes respiratory rehabilitation during the
daytime.
Considering the sympathoinhibitory and anxiolytic ac-
tion of Dex, there is the possibility that Dex might reduce
the incidence of AF, one of the major complications after
cardiovascular surgery. Therefore, we conducted this
retrospective study to determine whether Dex affected the
incidence of AF in cardiovascular surgery patients after
extubation.
Methods
This was a retrospective study that was approved by the
ethics committee at Yamagata University Faculty of
Medicine. Due to the retrospective study design under
our routine clinical practice, written informed consent
of an individual patient was waived.Sedation protocol in our ICU
In our ICU, we administered propofol and fentanyl
throughout the day to patients under mechanical venti-
lation after cardiovascular surgery to produce Richmond
Agitation Sedation Scale (RASS) between −2 and −3.
The administration rate of propofol was 0.5–3 mg/kg/h
and that of fentanyl was 0.05–2 μg/kg/h. We started a
spontaneous breathing trial (SBT) when the patient’s
body temperature, white blood cell count, and C-
reactive protein levels tended to recover normally after
surgery. We decided to extubate when patients met our
standards for tracheal extubation: a PaO2/FIO2 ratio
was >200 (at positive end-expiratory pressure of 5
cmH2O and pressure support of 5 cmH2O), PaCO2 was
35–50 mmHg, respiratory rate was <25 breaths per mi-
nute, and patients were also capable of deep breathing
and had small amount of sputa during SBT. Just before
tracheal extubation, we stopped the administration of
propofol and kept infusing fentanyl only if patients felt
some pain. After weaning patients from mechanical ven-
tilation, the use of Dex as a sedative agent on the day of
extubation was left to the discretion of the attending
physician, intensivist, or cardiothoracic surgeon. When
sedation with Dex was started, it was administered dur-
ing 2 nights only from 8 p.m. to 6 a.m. following the
protocol of Dex administration in our ICU. We set 2
nights after tracheal extubation as the basic administra-
tion period because of the restriction on Dex administra-
tion of 24 h at that time. Dex was adjusted to a rate of
0.2–0.7 μg/kg/h to obtain adequate sedation as assessed
by RASS. If patients seemed to be delirious with inco-
herent behavior and distraction, we administrated halo-
peridol without increasing the Dex dose. Dex could be
used throughout the day when patients were agitated or
suffered from delirium during the daytime.
Patients
The majority of patients in our ICU had undergone
cardiovascular surgery. We included a total of 133 adult
patients in this study who were admitted to our ICU
after cardiovascular surgery from November 2009 to
November 2010. We excluded 36 patients who had
chronic AF or a past history of paroxysmal AF in the
preoperative or intubation period and 6 patients who
died in the ICU after surgery. Of the remaining patients,
48 received Dex and 43 did not receive any sedative
drugs. We excluded 30 patients who received Dex due
to protocol deviation: 11 patients received all-day ad-
ministration, and 19 were sedated for only 1 night. We
also excluded patients under 60 years old or over
85 years old to be age-matched in both groups, because
the patients over 80 years were included only in the
group administered with Dex and the patients under
60 years only in the group not administered with Dex.
Fig. 2 Definition of the observation period. Day 1: 24 h from 8 p.m.
on the extubation day to 8 p.m. on the next day. Day 2: 24 h from
8 p.m. on the next day to 8 p.m. 2 days later following the
extubation day. Dex dexmedetomidine
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18 that received Dex and 14 patients from the 43 that
did not receive Dex or any sedative drugs. The remaining
patients were divided into a Dex group (n = 16) and a
non-Dex group (n = 29) (Fig. 1).
Data collection
The primary outcome was the incidence of AF in cardio-
vascular surgery patients after tracheal extubation. We
retrospectively examined the ICU records to identify the
occurrence of AF during the 2-day period after tracheal
extubation, because Dex was generally administered dur-
ing this period at that time. We defined the observation
period as follows: 24 h from 8 p.m. on the extubation
day to 8 p.m. on the next day as day 1 and from 8 p.m.
on the next day to 8 p.m. 2 days later following the extu-
bation day as day 2 (Fig. 2). Our ICU staff recorded the
onset of AF in the ICU chart when they detected AF on
the electrocardiogram that was displayed on the bedside
monitor. We diagnosed AF whether it was temporary or
continuous, and the diagnosis was made without review-
ing the electrocardiogram. The following demographics
and risk factors for AF were also collected from the ICU
chart: age, gender, body mass index (BMI), the Acute
Physiology and Chronic Health Evaluation (APACHE) II
score during the first 24 h of ICU stay, the Sequential
Organ Failure Assessment (SOFA) score just before tra-
cheal extubation, ICU stay, intubation day, hypertension,
valvular disease, heart failure, left ventricular hyper-
trophy, diabetes, smoking, heart rate (HR), central ven-
ous pressure (CVP), body temperature, white blood cell
count, serum level of C-reactive protein, catecholamine
(dopamine and/or dobutamine) use, beta-blocker use,Fig. 1 Patients enrollment flow diagram. AF atrial fibrillation, Dex dexmedeand fentanyl use [18]. For sequential data such as HR,
CVP, and body temperature, we used the 11 a.m. records
in the ICU charts as the patients’ daytime data and the
11 p.m. records as the nighttime data.
Statistics
All statistical analyses were performed with R software
(version 2.13.0). Variables were compared between
groups using an unpaired t-test or a chi-squared test.
The factors associated with AF were determined by
Fisher’s exact analysis and multivariate logistic regres-
sion analysis. To control for potential confounders, a
multiple logistic regression model with forward selec-
tion was used. The entry probability was p = 0.15 or
less, and the removal probability was p > 0.15 in Fisher’s
exact analysis [19]. A p value <0.05 was regarded as
significant in this study.
Results and discussion
Results
There was no difference between the Dex group and the
non-Dex group in age (71.3 vs 69.6 years.) or gendertomidine
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during the first 24 h of ICU stay was statistically higher
in the Dex group (12.4 vs 10.5, p = 0.048), the SOFA
score just before tracheal extubation was not signifi-
cantly different (5.6 vs 6.1). The number of intubation
days was greater in the Dex group (4.4 vs 2.3 days);
however, there was no difference in the length of ICU
stay (7.6 vs 6.0 days).
Diabetes, one of the risk factors for AF, was higher in
the non-Dex group, while the other risk factors (BMI,
hypertension, valvular disease, heart failure, ventricular
hypertrophy, and smoking) were not significantly differ-
ent between the two groups (Table 1). All patients were
admitted to our ICU after cardiovascular surgery, such
as valve replacement (31.3 % [5/16] vs 41.4 % [12/29]),
coronary artery bypass graft (CABG) (25.0 % [4/16] vs
44.8 % [13/29]), valve replacement + CABG (6.3 % [1/16]
vs 3.4 % [1/29]), thoracoabdominal aorta replacement
(12.5 % [2/16] vs 0 % [0/29]), total arch replacement +
CABG (18.8 % [3/16] vs 0 % [0/29]), and other proce-
dures (6.3 % [1/16] vs 10.3 % [3/29]). The main operative
procedures were valve replacement and CABG in both
groups. More patients in the Dex group tended to
undergo major surgeries such as thoracoabdominal aorta
replacement or total arch replacement.
We examined patients’ data during the 2-day period
after tracheal extubation by review of the ICU records.
The average rate of Dex infusion during the nighttime in
the Dex group was 0.3 ± 0.2 μg/kg/h. We did not use the
hypnotic drugs during the observation period. There
was statistically no difference in HR during the daytime,Table 1 Patient demographic and baseline characteristics
Dex group
Age (years) 71.3 ± 6.2
60–69/70–79/80–85(n) 6/9/1
Gender (M/F) 12/4
BMI (kg/m2) 22.3 ± 2.5
APACHE II score during the first 24 h of ICU stay 12.4 ± 3.1
SOFA score just before tracheal extubation 5.6 ± 1.4
ICU stay (days) 7.6 ± 3.4
Intubation (days) 4.2 ± 3.2
Hypertension [n, (%)] 12 (75.0)
Valvular disease [n, (%)] 7 (43.8)
Heart failure [n, (%)] 0 (0)
Left ventricular hypertrophy [n, (%)] 6 (37.5)
Diabetes [n, (%)] 1 (6.3)
Smoking [n, (%)] 10 (62.5)
HR on preoperative ECG (bpm) 62.4 ± 11.1
The data are presented as mean ± standard deviation or the number of patients (%
BMI body mass index, APACHE II score Acute Physiology and Chronic Health Evaluat
Assessment score, HR heart rate, ECG electrocardiogramCVP, body temperature, serum level of C-reactive pro-
tein, catecholamine (dopamine and/or dobutamine) use,
beta-blocker use, and the amount of fentanyl between
the two groups. HR during the nighttime was signifi-
cantly lower in the Dex group (Table 2).
AF occurred in one patient in the Dex group (6.3 %)
and in ten patients in the non-Dex group (34.5 %)
during the 2-day observation period after tracheal extu-
bation. The lower incidence of AF in the Dex group was
statistically significant (p = 0.035) (Table 3). In univariate
analysis, none of the risk factors for AF was significantly
associated with AF. Multivariate logistic regression ana-
lysis using age, Dex use, and beta-blocker use, extracted
because their p values in univariate analysis were not ex-
ceeding 0.15, showed that Dex use was associated with the
occurrence of AF (p = 0.045, odds ratio 9.75 [1.05–90.8])
(Table 4).
Discussion
Our results suggested that the incidence of AF decreased
in cardiovascular surgery patients who received Dex
after tracheal extubation. The incidence of AF was asso-
ciated with Dex administration based on multivariate
logistic regression analysis.
There are different views about the relationship be-
tween Dex and AF based on previous clinical studies. It
was stated that Dex had an antiarrhythmic property dur-
ing the perioperative period in patients undergoing
surgery for congenital heart disease, which was produced
through its action on cerebral imidazoline receptors [3].
On the other hand, it was reported that alpha-2 agonists(n = 16) Non-Dex group (n = 29) p value
69.6 ± 6.7 0.4
15/13/1
17/12 0.27
22.3 ± 3.6 0.36
10.5 ± 2.9 0.048
6.1 ± 1.3 0.22
6.0 ± 2.1 0.06







66.3 ± 13.6 0.33
)
ion II score, ICU intensive care unit, SOFA score Sequential Organ Failure
Table 2 Patients’ data by ICU chart review in the Dex and the non-Dex groups
Day 1 Day 2
Dex group (n = 16) Non-Dex group (n = 29) p value Dex group (n = 16) Non-Dex group (n = 27) p value
Dex dose (μg/kg/h) 0.3 ± 0.1 0 0.3 ± 0.2 0
HR daytime (bpm) 79.5 ± 7.4 84.2 ± 12.8 0.18 79.0 ± 8.7 82.8 ± 14.9 0.37
HR nighttime (bpm) 73.5 ± 13.0 84.4 ± 9.3 0.002 69.9 ± 11.3 84.3 ± 9.6 <0.001
CVP (mmHg) 6.6 ± 2.7 7.5 ± 2.7 0.36 6.9 ± 2.4 7.5 ± 3.4 0.59
Body temperature (°C) 37.5 ± 0.4 37.7 ± 0.4 0.08 37.5 ± 0.5 37.6 ± 0.4 0.27
WBC (103/μl) 12.3 ± 4.8 11.8 ± 4.3 0.76 10.5 ± 4.7 10.2 ± 3.3 0.80
CRP (mg/dl) 8.8 ± 4.6 9.2 ± 5.1 0.82 7.8 ± 4.4 8.2 ± 4.0 0.76
Catecholamine use ≧3 μg/kg/m 2/16 9/29 0.17 5/16 5/27 0.27
Beta-blocker use 8/16 13/29 0.74 8/16 13/27 0.91
Amount of fentanyl (μg) 383.1 ± 339.2 429.3 ± 346.7 0.67 121.9 ± 140.6 179.3 ± 231.9 0.37
The data are presented as mean ± standard deviation or the number of patients (%). Day 1: 24 h from 8 p.m. on the extubation day to 8 p.m. on the next day.
Day 2: 24 h from 8 p.m. on the next day to 8 p.m. 2 days later following the extubation day. Catecholamine: dopamine and/or dobutamine
ICU intensive care unit, Dex dexmedetomidine, HR heart rate, CVP central venous pressure, WBC white blood cell count, CRP serum level of C-reactive protein
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and also, Dex was not associated with a significant re-
duction in the risk of AF in adult patients [15]. In these
previous literatures compared with our study, there was
a difference in that the patients received a 24-h adminis-
tration of Dex during mechanical ventilation just after
ICU admission. Whereas, the patients in our study re-
ceived Dex only during the nighttime after tracheal
extubation. We considered that this difference of ad-
ministration of Dex would lead to another viewpoint on
the relation between DEX and AF in our study. There
were few studies focused on the relationship between
Dex and AF after tracheal extubation.
AF was reported to occur in almost 50 % of patients
after major cardiovascular surgeries such as total arch
replacement and was higher in these patients than in
those with other cardiovascular surgeries such as valve
replacement and CABG [20, 21]. It was also reported
that the occurrence of AF after such major surgeries
peaked on day 2, and about half was widely distributed
as well after day 3 [22]. In our study, the surgical stress
in the Dex group was considered more severe taking
into account the operative procedure and the APACHE
II score during the first 24 h of ICU stay. It was consid-
ered that the intubation day was longer in the Dex group
because they underwent more major surgeries than inTable 3 Incidence of atrial fibrillation during the 2-day observation
Incidence of atrial fibrillation Total [n, (%)]
Day 1
Day 2
Day 1: 24 h from 8 p.m. on the extubation day to 8 p.m. on the next day. Day 2: 24
extubation daythe non-Dex group. However, the incidence of AF was
significantly lower in the Dex group. This different find-
ing compared with previous studies may have been due
to the effect of Dex in addition to the fact that we col-
lected all patient data after tracheal extubation. It was
presumed that patients in both groups had a similar
clinical status after extubation in our study, because
there was no difference in the SOFA score just before
tracheal extubation between the two groups. Further-
more, many patients in the non-Dex group that had a
high incidence of AF had diabetes that has been re-
ported to be a risk factor for AF; however, diabetes was
not associated with the incidence of AF in the univariate
analysis (p = 0.72).
Dex has unique effects to provide sedation and relieve
anxiety by acting on alpha-2 receptors in the locus ceru-
leus and directly attenuating the sympathetic nerve in
the spinal cord [15]. Dex is considered to induce a seda-
tive response that exhibits properties similar to those of
natural sleep, because it represents a similar pattern of
c-Fos expression as seen during normal nonrapid eye
movement sleep (a decrease in activity in the locus ceru-
leus and tuberomammillary nucleus and an increase in
the ventrolateral preoptic nucleus) [23]. Natural sleep at
night facilitates recovery from physical and mental fa-
tigue. Therefore, endogenous catecholamine productionperiod after tracheal extubation
Dex group Non-Dex group p value
1/16 (6.3) 10/29 (34.5) 0.035
1/16 (6.3) 6/29 (20.7) 0.20
0/16 (0) 7/27 (25.9) 0.05
h from 8 p.m. on the next day to 8 p.m. 2 days later following the
Table 4 Risk factors of atrial fibrillation















Left ventricular hypertrophy 1
Diabetes 0.72
Smoking 0.48




Age 0.13 1.1 (0.97–1.24)
Dexmedetomidine 0.045 9.75 (1.05–90.8)
Beta-blocker 0.36 0.69 (0.32–1.51)
Univariate analysis was conducted by Fisher’s exact test. Multivariate logistic
regression analysis was conducted using age, Dex, and beta-blocker, extracted
because their p values in univariate analysis were not exceeding 0.15
BMI body mass index, CRP serum level of C-reactive protein, APACHE II score
Acute Physiology and Chronic Health Evaluation II score, SOFA score Sequential
Organ Failure Assessment score
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is possible that this may account for the reduction in AF
by Dex. In addition, Dex might have a direct antiar-
rhythmic effect to reduce the incidence of AF in our
ICU patients. Cerebral nuclei that are rich in alpha-2
receptors are activated by Dex, such as the dorsal motor
nucleus of the vagus nerve, the nucleus ambiguous, and
the nucleus of the tractus solitarius. The enhanced vagal
activity affects myocyte cyclic adenosine monophosphate
and the calcium ion current and consequently leads to
prolongation of repolarization and the effective refrac-
tory period. This evidence supports a hypothesis for an
antiarrhythmic action of Dex [24].
An important limitation of our study is that it is a
retrospective study. The reasons are unclear why physi-
cians in our ICU decided to use Dex to provide sedation
after tracheal extubation. It was just left to the discretion
of the attending physician at that time and was never
intentionally made. Furthermore, it is possible that wedid not accurately diagnose AF because we evaluated the
presence of AF based only on the ICU chart, and we
cannot review the electrocardiogram at the time of AF
occurrence. There is also a limitation that the patients
have been examined at different periods after surgery in
the Dex group (4.2 ± 3.2 days) and the non-Dex group
(2.3 ± 1.0 days). It has been reported that a peak of post-
operative AF was day 2 focused on CABG and valve sur-
gery, and more than 95 % of AF episodes occurred
before day 5 [2]. While it has been reported that the dis-
tribution of onset of AF after major surgeries such as
thoracoabdominal aorta replacement and total arch re-
placement showed a peak on day 2, but also about half
was widely distributed as well after day 3 [22]. In the
DEX group in our study, 31.2 % patients underwent
such major surgeries, so AF possibly occurred at the ob-
servation period. Therefore, we consider that it is worth
comparing the occurrence of AF at the different periods
between two groups.
Conclusions
In our study, the incidence of AF after tracheal extuba-
tion decreased significantly in cardiovascular surgery
patients that received Dex only during the nighttime. It
is probably because Dex has unique effects to reduce
sympathetic tone and endogenous catecholamine pro-
duction as well as to promote adequate sedation like
natural sleep. Because this study is a small retrospect-
ive study, there are some limitations on the differences
on the observation period, the operative procedure,
and the patient characteristics such as diabetes between
the Dex group and the non-Dex group. A prospective in-
vestigation making a distribution of the background of the
study is needed in a larger population to confirm the effect
of Dex on AF reduction.
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